{"id":"mt1013","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PDE4 inhibition is thought to modulate inflammatory responses and potentially treat various conditions.","oneSentence":"MT1013 is a small molecule that targets the PDE4 enzyme.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:15.607Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT06747247","phase":"PHASE2","title":"A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","startDate":"2023-04-07","conditions":"Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis","enrollment":98},{"nctId":"NCT06690242","phase":"PHASE2","title":"MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","startDate":"2024-11-04","conditions":"Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis","enrollment":115},{"nctId":"NCT07284043","phase":"PHASE1","title":"A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism","status":"RECRUITING","sponsor":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","startDate":"2025-11-30","conditions":"Hemodialysis Subjects With Secondary Hyperparathyroidism","enrollment":6},{"nctId":"NCT07122401","phase":"PHASE3","title":"Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism","status":"RECRUITING","sponsor":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","startDate":"2025-09-30","conditions":"Secondary Hyperparathyroidism, Chronic Kidney Disease","enrollment":424},{"nctId":"NCT06976177","phase":"PHASE2","title":"Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis","status":"RECRUITING","sponsor":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","startDate":"2024-06-07","conditions":"Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis","enrollment":310},{"nctId":"NCT04783090","phase":"PHASE1","title":"MT1013 Clinical TRIAL In Healthy Subject","status":"COMPLETED","sponsor":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","startDate":"2021-06-28","conditions":"Healthy Volunteer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MT1013","genericName":"MT1013","companyName":"Shaanxi Micot Pharmaceutical Technology Co., Ltd.","companyId":"shaanxi-micot-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MT1013 is a small molecule that targets the PDE4 enzyme. Used for Moderate to severe plaque psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}